UNSPSC 51161812: Combination chlorpheniramine acetaminophen

This classification denotes a combination cough and cold and antiallergy drug. The first component of this drug is a histamine-1 receptor antagonist with the molecular formula C16H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U, chemically known as 3-(p-chlorophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but generally known as chlorphenamine, which bears US NIH Compound Identifier 2725.

UNSPSC 51161812 Combination chlorpheniramine acetaminophen is a Commodity code that in recent state and local procurement activity covers a narrower scope than the code name suggests — state and local health systems are actually soliciting parenteral products, intravenous solutions, naloxone, and drug deactivation systems rather than the specific combination antihistamine-analgesic compound named in the code. The Department of Corrections and county health authorities are the primary issuing bodies using this code designation, each procuring medical supplies and pharmaceuticals for correctional facilities and community health programs. The work involves supplying specialized medical products with tight delivery windows, documented clinical preparation and monitoring capability, and compliance with state licensure, insurance, and background-clearance requirements.

Washington State Department of Corrections posted RFQ RFQQK13020 on September 8, 2026, due October 7, 2026, soliciting parenteral nutrition solutions, intravenous products, and related supplies across eight correctional facilities spanning three regions (West, Central, and East Washington), with a contract term of November 26, 2026 through June 30, 2030 and potential awards to up to three contractors per region; the RFQ includes set-asides for small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), certified through state agencies. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though the listed response date of July 26, 2023 is a historical record. Recent activity concentrates in Washington and Florida, with the Washington opportunity representing the larger and more active procurement pipeline for this code classification at the state level.